In the era of targeted therapies, precision is no longer optional—it is the foundation of successful drug discovery and clinical development. Relying on the wrong data during early research can often lead to costly late-stage drug development and commercialization failures, making diagnostic-level lab data essential for the definitive insights needed to confidently advance the right therapies.
Explore the key characteristics of different real-world data (RWD) sources to help you assess what you are currently using and what you may be missing to drive maximum impact from the start of your next drug’s journey.
Interested in learning more about how we can help? Consider the following:
See how a precision-driven approach reduces risk, optimizes development strategies, and accelerates outcomes across the life cycle.
Request a proposal to determine the volume of deidentified lab data available to support your early-stage drug discovery and biomarker identification efforts.
Your Privacy Choices
Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services. Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services.
Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.
